ASH 2020: Bispecifics Battle For Share Of BCMA Market In Myeloma

CAR-T Therapies Will Beat T-Cell Engagers To Market

 
• By Mandy Jackson
  
BCMA-targeting bispecifics are racing from Phase I into Phase II studies • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D